Xeris Biopharma (NASDAQ:XERS) Stock: Insider Kevin Mcculloch Sells 25,000 Shares

November 7, 2026 by InsiderTrades.com

Key Points

Insider Kevin McCulloch sold 25,000 Xeris Biopharma shares for $312,250 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 1.58%; he still owns about 1.56 million shares.
Xeris beat third-quarter expectations, reporting earnings of $0.06 per share versus $0.03 expected and revenue of $107.23 million versus $101.68 million forecast.
Analysts including Oppenheimer and HC Wainwright raised their price targets; the stock opened at $15.20 after a reported 16.2% gain.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Kevin McCulloch sold 25,000 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $12.49, for a total transaction of $312,250.00. Following the sale, the insider owned 1,559,208 shares in the company, valued at approximately $19,474,507.92. This trade represents a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

On Monday, November 2nd, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $10.23, for a total transaction of $153,450.00.
On Thursday, October 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $9.41, for a total value of $141,150.00.
On Monday, September 28th, Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $10.00, for a total value of $250,000.00.
On Tuesday, September 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.49, for a total transaction of $127,350.00.

Xeris Biopharma Trading Up 16.2%

Shares of Xeris Biopharma stock opened at $15.20 on Friday. Xeris Biopharma Holdings, Inc. has a 12-month low of $5.25 and a 12-month high of $15.21. The stock has a market cap of $2.77 billion, a price-to-earnings ratio of -303.94 and a beta of 0.61. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00. The company has a fifty day simple moving average of $9.62 and a 200-day simple moving average of $7.62.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of $0.03 by $0.03. The business had revenue of $107.23 million for the quarter, compared to analysts' expectations of $101.68 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. On average, equities analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current fiscal year.

Institutional Investors Weigh In On Xeris Biopharma

Hedge funds have recently added to or reduced their stakes in the company. Knights of Columbus Asset Advisors LLC acquired a new position in Xeris Biopharma during the 3rd quarter worth approximately $1,275,000. StoneX Group Inc. acquired a new stake in shares of Xeris Biopharma in the 3rd quarter valued at approximately $142,000. Pictet Asset Management Holding SA boosted its stake in shares of Xeris Biopharma by 13.7% in the third quarter. Pictet Asset Management Holding SA now owns 34,107 shares of the company's stock valued at $326,000 after buying an additional 4,108 shares in the last quarter. AlphaCentric Advisors LLC boosted its stake in shares of Xeris Biopharma by 4.2% in the third quarter. AlphaCentric Advisors LLC now owns 48,489 shares of the company's stock valued at $464,000 after buying an additional 1,940 shares in the last quarter. Finally, Commonwealth Equity Services LLC grew its holdings in Xeris Biopharma by 3.6% during the third quarter. Commonwealth Equity Services LLC now owns 213,337 shares of the company's stock worth $2,040,000 after acquiring an additional 7,482 shares during the period. Institutional investors and hedge funds own 42.75% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Barclays lifted their target price on shares of Xeris Biopharma from $12.00 to $14.00 and gave the company an "overweight" rating in a report on Tuesday, October 6th. HC Wainwright raised their price objective on shares of Xeris Biopharma from $10.00 to $18.00 and gave the stock a "buy" rating in a research report on Friday. Oppenheimer reissued an "outperform" rating and set a $21.00 price objective (up from $18.00) on shares of Xeris Biopharma in a research report on Friday. Weiss Ratings lowered shares of Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th. Finally, Leerink Partners upped their target price on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an "outperform" rating in a report on Thursday, September 10th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Xeris Biopharma has an average rating of "Moderate Buy" and a consensus target price of $16.20.

View Our Latest Stock Analysis on Xeris Biopharma

Key Headlines Impacting Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

Positive Sentiment: Q3 results beat expectations: Xeris reported earnings of $0.06 per share versus a $0.03 consensus estimate, while revenue of $107.23 million exceeded forecasts of $101.68 million. The results provide evidence of stronger-than-expected performance. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
Positive Sentiment: Analysts raised targets: Oppenheimer reaffirmed its “outperform” rating and lifted its target to $21 from $18. HC Wainwright kept a “buy” rating and raised its target to $18 from $10. These revisions suggest greater optimism about Xeris’s prospects. Oppenheimer ratings HC Wainwright ratings
Positive Sentiment: Recorlev sales outlook: CEO John Shannon reportedly sees the drug approaching $1 billion in annual sales three to four years earlier than previously expected, a potentially meaningful growth driver. CEO comments on Recorlev sales outlook
Neutral Sentiment: Insider Kevin McCulloch sold 25,000 shares under a pre-arranged Rule 10b5-1 plan, a modest reduction; he retained more than 1.55 million shares. SEC Form 4 filing
Negative Sentiment: Cautious analyst view: Piper Sandler reaffirmed “neutral” despite raising its target to $12 from $8. That target remains below the share price cited in the report, signaling valuation concerns. Piper Sandler ratings

About Xeris Biopharma

(Get Free Report)

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris' commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing's syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.